A low dose monthly emicizumab for prophylaxis among Thai hemophilia A patients with and without inhibitor
- Conditions
- A total of 8-10 patients with hemophilia A will be recruited in the current studylow doseemicizumabThai hemophiliaThai hemophilia A
- Registration Number
- TCTR20210725001
- Lead Sponsor
- Division of Pediatric Hematology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Enrolling by invitation
- Sex
- Male
- Target Recruitment
- 10
Inclusion Criteria
1. Patients with moderate to severe hemophilia A (factor VIII activity less than 3%) with and without inhibitor.
2. Age 2 years or older
3. Patients are able to access to treatment for acute bleeding within 2 hours
4. Experienced low-dose prophylaxis or at least 5 bleeds in 6 months in episodic treatment
Exclusion Criteria
1. Other coagulation disorders
2. Liver or renal diseases
3. Conditions that may increase risk of bleeding
4. Concomitant disease, condition or abnormality that could interfere with study conduct or pose unacceptable risk to patients
5. Required elective surgery
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method bleeding rate before and one year counting
- Secondary Outcome Measures
Name Time Method quality of life before, 3 ,6,9 and 12 months score